Drugs / Human Urinary Kallidinogenase
Human Urinary Kallidinogenase
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07283159 | Jan 2026 → Sep 2027 expected | ischemic stroke | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 2 | NCT02259738 | Jan 2013 → Jun 2014 | cerebral infarction | XuanwuH 2 | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04102956 | Jul 2017 → Mar 2019 | ischemic stroke | The Second Hospital of Hebei Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02562183 | Aug 2015 → Nov 2018 | cerebral infarction | Techpool Bio-Pharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03431909 | Jan 2014 → Oct 2016 | ischemic stroke | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07483281 | May 2026 → Mar 2028 expected | ischemic stroke | China-Japan Union Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06848894 | Mar 2025 → Dec 2026 expected | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06211712 | Apr 2024 → Jun 2025 overdue | ischemic stroke | Huashan Hospital | Recruiting | No outcome recorded |
| — | NCT06132880 | Dec 2023 → Aug 2026 overdue | ischemic stroke | Beijing Tsinghua Chang Gung Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06380699 Comparator | Mar → Nov 2023 | ischemic stroke | Changzhou Qianhong Bio-pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Urinary Kallidinogenase | “Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute...” PMID 28265861 ↗ Mar 2017 |
| Known as | HUK | “Human urinary kallidinogenase (HUK) was approved by the China Food and Drug Administration (CFDA) in 2005 for the treatment of mild to moderate AIS” PMID 28265861 ↗ Mar 20173“Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine.” NCT07283159 ↗ “Human urinary kallidinogenase (HUK)” NCT03431909 ↗ “Human urinary kallidinogenase (HUK)” NCT06848894 ↗ |
| Known as | Kallikrein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04102956 ↗ |
| Known as | Urinary Kallidinogenase | “Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine.” NCT07283159 ↗ |
| Modality | Protein / enzyme biologic | “Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine.” NCT07283159 ↗ |
| Route | Intravenous | “All patients receive HUK by intravenous drip once daily for 21 consecutive days.” PMID 28265861 ↗ Mar 2017 |